

Users Guide

May 2023




60TH ANNIVERSARY

TABLE OF CONTENTS

Section 1: Home Page Navigation	3
1. Top left menu	3
2. Top right menu.....	3
3. Search box menu	3
4. Middle menu.....	3
5. Bottom menu.....	3
Section 2: Search	4
Section 3: Drug Updates	12
Section 4: Pill Identifier	13
Section 5: Interactions Checker	16
Section 6: Browse	19
Section 7: Tools and Resources	22
7.1 Tools.....	22
• Don't Rush to Crush.....	22
• Drug-Herb Interactions the "IM Gateway"	23
• MIMS Interaction Checker	23
• Pill Identifier	23
• CYP450 Drug Interactions.....	24
• Inhaler Technique Videos	24
• Medicines in Pregnancy	25
• IV Compatibility	26
7.2 Resources.....	27
• Drug in Sport – WADA Guide.....	277
• Medicines In Pregnancy Information – TGA	277
• PBS Brand Substitution	288
• Oral Contraceptives currently available in Australia	28
Section 8: Glossary of Terms	29

Section 1: Home Page Navigation

The home page is divided into 5 key areas:




1. **Top left menu** – Navigation bar that contains shortcuts for “Search”, “Browse”, “Interaction Checker”, “Pill Identifier”, and “Tools and Resources”.
2. **Top right menu** – Consists of “Data Version” and “Three-line icon” which contains admin tools, history of recent searches, and saved searches.
3. **Search box menu** – Allows entry of text to perform a simple search for medicine names, ingredients, therapeutic classes, indications, or company names.
4. **Middle menu** – Consists of “Drug Updates” of the current version and “Shortcuts” to Tools and Resources.
5. **Bottom menu**
 - **MIMS Australia. All rights reserved.** – Displays MIMS copyright statement.
 - **About MIMS** – Opens the eMIMSplus Website.
 - **Privacy** – Displays the MIMS privacy policy.
 - **Feedback** – Opens up a form for feedback, suggestions, or comments.
 - **Terms & Conditions** – displays terms and conditions of use of the eMIMSplus website and product.

Section 2: Search

eMIMSplus provides a wide variety of medicines information that can be found using its search feature.

There are two ways to start the Search:



1. “Search” in the navigation bar on the top left menu OR
2. Use the search box on the homepage to begin a drug search.

To get started with the drug search:



1. Enter the first few letters of a product brand name, generic name/ingredient, indication, or therapeutic class and select from the drop-down list e.g., Los (the first three characters will show search suggestions)

OR

Enter keyword (s) in the search box such as product name e.g., Losartan.

2. Choose from the drop-down search suggestion.
3. Click on Search.


Note: You can also search by Indication, Therapeutic Class, OR Manufacturer in the product information search. You can also search by a generic synonym e.g., “Albuterol” and will give results on “Salbutamol” which is the same.

The Product Information results appear showing the information below:


The screenshot displays the MIMS Search Results interface for 'Losartan potassium'. At the top, a blue header reads 'MIMS Search Results'. Below this, the search results are shown for 'Losartan potassium', indicating 2 total results. The first result is 'Cozaar Tablets' by 'Organon Pharma Pty Ltd'. The interface includes several numbered callouts (1-5) pointing to specific elements: 1 points to the brand name 'Cozaar Tablets'; 2 points to the generic name 'Losartan potassium'; 3 points to the manufacturer 'Organon Pharma Pty Ltd'; 4 points to the MIMS Class 'Antihypertensive agents'; and 5 points to a row of navigation buttons: 'Abbreviated PI', 'Full PI', 'CMI', 'Crush?', 'Drug Interactions', and 'Herbal Interactions'. The main content area provides clinical information: 'Use: ARB. Hypertension (± other antihypertensives eg thiazide diuretics); renal disease progression delay in hypertensive type 2 diabetes with proteinuria (urinary albumin:creatinine ≥ 300 mg/g)'; 'Dose: ± Usual initial, maintenance dose: 50 mg once daily; consider 25 mg twice daily before dose incr if response inadequate; max 100 mg/day in 1 or 2 doses'; 'Volume depletion: initially 25 mg once daily'; and 'Hepatic impairment history: consider decr dose'. Under 'MIMS Class', 'Antihypertensive agents' is highlighted. Under 'Product Images', two images of 'Cozaar 50 mg' tablets are shown.

1. Clicking on the brand name will display the Full PI, Abbreviated PI, CMI, and Crush information (when available) according to the default navigation option set in the preferences.
2. Use this link to find other products containing the same generic ingredient.
3. Click to display the manufacturer details, including a list of all their products, address, and contact details.
4. Use this link to find products in the same therapeutic class.
5. Select 'Abbreviated PI', 'Full PI', 'CMI', 'Crush?', 'Drug Interactions', and 'Herbal Interactions'.


When the product name is selected, the Product information page will show the following:




1. The Brand name, Generic name, Manufacturer, Therapeutic Class, Pregnancy category, ARTG (with an available hyperlink to “Report an Adverse Reaction”), Use in Sports, and MIMS Revision Date.
2. This page also shows the product image (when available).
3. You can also find helpful features such as:
 - **“Email”** – clicking the email will launch a new Send Email Dialog box. This allows you to send the PDF as an attachment to your patients without sending your email details.



- **“PDF”** – the document will automatically convert into a PDF file.



- **“Print”** – will prepare the document for printing.



- **“Bookmark”** – This will allow you to save a particular drug search as a favourite (Refer to the Three-line icon on the top right menu of the homepage).

4. The Product Information page is also presented with the following information.

- **Abbreviated Product Information** which includes uses, precautions, adverse effects, and available products with dosage.

Cozaar
Losartan potassium

Company: Organon Pharma Pty Ltd
MIMS Class: Antihypertensive agents
Use in Pregnancy: D
ARTG: Registered Medicine
Sports: Permitted in sport
MIMS Revision Date: 01 June 2022

Product Images: Cozaar 50 mg

Abbreviated PI | Full PI | CMI | Crush? | Drug Interactions | Herbal Interactions | CYP450

Use
AR8. Hypertension (± other antihypertensives eg thiazide diuretics); renal disease progression delay in hypertensive type 2 diabetes with proteinuria (urinary albumin:creatinine ≥ 300 mg/g)

Contraindications
Concomitant aliskiren in diabetes; pregnancy (esp 2nd, 3rd trimesters, disc as soon as poss when pregnancy detected)

Precautions
Volume depletion (eg high dose diuretic therapy), electrolyte imbalance (correct preadmin); hepatic impairment history; ClCr < 30 mL/min; RAAS dependent renal function eg severe CHF; bilateral renal artery stenosis, stenosis of artery to solitary kidney; dual RAAS blockade (monitor BP, renal function, electrolytes); aspirin, penicillin hypersensitivity; elderly; lactation (disc); children; neonates exposed in utero (monitor for hypotension, oliguria, hyperkalaemia)

- **Full Product Information** that includes qualitative and quantitative composition, pharmaceutical form, clinical particulars, pharmacological properties & particulars, medicine schedule, table of changes, and dates of approval

Cozaar
Losartan potassium

Company: Organon Pharma Pty Ltd
MIMS Class: Antihypertensive agents
Use in Pregnancy: D
ARTG: Registered Medicine
Sports: Permitted in sport
MIMS Revision Date: 01 June 2022

Product Images: Cozaar 50 mg

Abbreviated PI | Full PI | CMI | Crush? | Drug Interactions | Herbal Interactions | CYP450

1 Name of Medicine
Losartan potassium.

2 Qualitative and Quantitative Composition
Cozaar (losartan potassium) 50 mg tablets.
Losartan potassium is a white to off-white free-flowing crystalline powder. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone.

List of excipients with known effect.
Lactose monohydrate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form
Cozaar (losartan potassium) 50 mg tablet: White, oval scored tablet, marked "952".

4 Clinical Particulars
4.1 Therapeutic Indications

- **Consumer Medicine Information (CMI)** – A written product information with instructions specifically for Consumers and approved by the TGA.

Cozaar
Losartan potassium

Company: Organon Pharma Pty Ltd
MIMS Class: Antihypertensive agents
Use in Pregnancy: D
ARTG: Registered Medicine
Sports: Permitted in sport
MIMS Revision Date: 01 June 2022

Product Images: Cozaar 50 mg

Abbreviated PI | Full PI | **CMI** | Crush? | Drug Interactions | Herbal Interactions | CYP450

COZAAR®
Losartan potassium

Consumer Medicine Information
What is in this leaflet

This leaflet answers some common questions about COZAAR. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking COZAAR against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What COZAAR is used for

COZAAR lowers high blood pressure, which doctors call hypertension.

COZAAR is also used to slow the progression of kidney disease in people who have type 2 diabetes mellitus (also known as non-insulin dependent diabetes) with protein in their urine (which doctors call proteinuria).

- **Don't Rush to Crush** - 'Crush?' is SHPA's Don't Rush to Crush (DRTC) guide for the safe administration of medicines and is linked to available products.

Cozaar
Losartan potassium

Company: Organon Pharma Pty Ltd
MIMS Class: Antihypertensive agents
Use in Pregnancy: D
ARTG: Registered Medicine
Sports: Permitted in sport
MIMS Revision Date: 01 June 2022

Product Images: Cozaar 50 mg

Abbreviated PI | Full PI | CMI | **Crush?** | Drug Interactions | Herbal Interactions | CYP450

Australian Don't Rush to Crush Handbook (Fourth edition)

LOSARTAN

Availability ¹	Brand name	Quick guide
Tablet 25 mg, 50 mg Each 50 mg tablet contains 4.24 mg of potassium	Cozaar, Cozavan	

Effect of food Food slows the rate but does not significantly affect the extent of absorption. Can be given without regard to food.¹

Warnings **Teratogen.¹ Do not crush or disperse the tablet if you are pregnant.** Contact a pharmacist or medicines information service for advice.

Dose changes Use the same dose when switching between the tablet and the extemporaneous suspension.²


Other May cause dry mouth and impaired or altered sense of taste.¹

What to do for people with enteral feeding tubes

Option 1 Disperse the tablet in 10–20 mL of water in an enteral syringe. Shake for 2 minutes.² See Method A for instructions.

Option 2 Some pharmacies can make a suspension from dispersed tablets.^{2,3} Contact a pharmacist or a compounding pharmacy.

- **Drug Interactions** - Identify potentially harmful combinations of medications or medications that may be unsuitable due to an allergy.



Cozaar
Losartan potassium

Company: Organon Pharma Pty Ltd
MIMS Class: Antihypertensive agents
Use in Pregnancy: D
ARTG: Registered Medicine
Sports: Permitted in sport
MIMS Revision Date: 01 June 2022


Product Images: Cozaar 50 mg

Drug Interactions 110 Allergy Check

Interaction Results
Showing results 1 to 20 of 110 total results.

Medicine	Route	Interacting medicine	Route	Severity	Documentation level
Cozaar [Losartan potassium]	Systemic	Amiloride hydrochloride	Systemic	Severe	Well Established
Cozaar [Losartan potassium]	Systemic	Captopril	Systemic	Severe	Well Established
Cozaar [Losartan potassium]	Systemic	Dibasic sodium phosphate dihydrate	Systemic	Severe	Good
Cozaar [Losartan potassium]	Systemic	Dibasic sodium phosphate dodecahydrate	Systemic	Severe	Good
Cozaar [Losartan potassium]	Systemic	Cilazapril	Systemic	Severe	Well Established

- **Herbal Interactions (IM Gateway)** - is an evidence-based clinical decision support module providing clinically proven drug and herb interactions.



Cozaar
Losartan potassium

Company: Organon Pharma Pty Ltd
MIMS Class: Antihypertensive agents
Use in Pregnancy: D
ARTG: Registered Medicine
Sports: Permitted in sport
MIMS Revision Date: 01 June 2022

Product Images: Cozaar 50 mg

Herbal Interactions

Select Ingredient: Losartan

Interaction Results
Showing results 1 to 1 of 1 total results.

Herb / Supplement / Food	Drug	Drug Class	Recommendation
Grapefruit juice	Losartan	Antihypertensive agents	Caution

- CYP450** – information that describes the interactions of a drug in terms of effects on cytochrome P450 isoenzymes - either because the drug in question or the drug with which it may interact is a substrate for, induces, or inhibits those enzymes.

Cozaar

Losartan potassium

Company: Organon Pharma Pty Ltd

MIMS Class: Antihypertensive agents

Use in Pregnancy: D


ARTG: Registered Medicine

Sports: Permitted in sport

MIMS Revision Date: 01 June 2022

Report an Adverse Reaction

Product Images



Cozaar 50 mg

Prescribed Medications

Losartan potassium ✓

Reference Molecule	1A2	2A6	2B6	2C9	2C19	2C8	2D6	2E1	3A4
Losartan potassium				substrate					substrate
Interacting Molecules	1A2	2A6	2B6	2C9	2C19	2C8	2D6	2E1	3A4
Abemaciclib									substrate
Abiraterone acetate						inhibitor	inhibitor		substrate
Acalabrutinib									substrate
Agomelatine		substrate		substrate	substrate				
Alectinib									substrate
Alfentanil									substrate
Alfentanil hydrochloride									substrate
Alfuzosin hydrochloride									substrate
Alprazolam									substrate
Ambrisentan								substrate	substrate
Amiodarone hydrochloride		inhibitor		inhibitor		substrate		inhibitor	inhibitor substrate
Amitriptyline hydrochloride		substrate		substrate	substrate			inhibitor substrate	substrate

Section 3: Drug Updates

This feature helps the users access monthly updates collated by the MIMS team. Upon logging in to the platform, the drug updates section highlights the number of updates added to the specific month of activity.

Clicking on the tabs will show you the information available for each update.



Drug Updates for May 2023		
	New Drugs	4
	New Indications	6
	New Contraindications	2
	Product Information Updates	183
	CMI Updates	147
	Discontinued Products	11


The above image shows an example of the “Drug Updates” for the May 2023 version. The “Drug Updates” section shows the following:

- **New Drugs** – new drugs added to the most current data version.
- **New Indications** – new indications added to the most current data version.
- **New Contraindications** – new contraindications added to the most current version.
- **Product Information Updates** – updates on pre-existing medicines.
- **CMI Updates** – updates on pre-existing consumer medicines information.
- **Discontinued Products** – products that have been deleted in the most current update.

Section 4: Pill Identifier

eMIMSplus offers a database of pill images that can be searched using the pill identifier tool.

From the homepage, select the tab “Pill Identifier” from the navigation bar at the top left menu.




Once you have accessed the “Pill Identifier” screen for Pill ID you can search by following these steps:

Select a **Shape, Colour, Scoring, Form, Class,** or **Company** from the drop-down menu
Enter a key word/s into the Marking search box.

By Shape:

Click the required shape to show all results of the chosen shape. One or more shapes can be selected for this field.



1. In the “Scoring”, select if there is scoring and ✕ if none
2. Click on the Symbol relevant to the search
3. For a broader search, click the arrow in the “Marking” box and choose from the drop-down selection

By Company/ Brand/ Ingredient/ Therapeutic Class

Type the Company Name, Brand Ingredient, or Therapeutic Class to show search results.

Pill Identifier

Identify medicines by colour, shape, markings, and other visual characteristics

Filters

Shape ▼

Colour ▼

Scoring/Markings/Symbols ▼

Company/ Brand/ Ingredients/
Therapeutic Class ▲

✕

Company Astellas Pharma Austral...

Search Results

Pill Identifier

Identify medicines by colour, shape, markings, and other visual characteristics

Filters

Shape ▼

Colour ▼

Scoring/Markings/Symbols ▼

Company/ Brand/ Ingredients/
Therapeutic Class ▲

Search Results

Filters: Company: Astellas Pharma Australia Pty Ltd ✕

[Clear filters](#)

Showing results 1 to 12 of 12 total results.

<p style="font-size: 0.8em; margin: 5px 0;">Advagraf XL 0.5 mg Capsules</p> <p style="font-size: 0.7em; margin: 0;">Form: Capsule Mims: Immunomodifiers Class: Colour: Yellow, Orange, Red Shape: Capsule Scoring: No</p>	<p style="font-size: 0.8em; margin: 5px 0;">Advagraf XL 1 mg Capsules</p> <p style="font-size: 0.7em; margin: 0;">Form: Capsule Mims: Immunomodifiers Class: Colour: White, Orange, Red Shape: Capsule Scoring: No</p>	<p style="font-size: 0.8em; margin: 5px 0;">Advagraf XL 3 mg Prolonged release capsule</p> <p style="font-size: 0.7em; margin: 0;">Form: Capsule Mims: Immunomodifiers Class: Colour: Orange, Orange, Red Shape: Capsule Scoring: No</p>	<p style="font-size: 0.8em; margin: 5px 0;">Advagraf XL 5 mg Capsules</p> <p style="font-size: 0.7em; margin: 0;">Form: Capsule Mims: Immunomodifiers Class: Colour: Pink, Orange, Red Shape: Capsule Scoring: No</p>	<p style="font-size: 0.8em; margin: 5px 0;">Betmiga 25 mg Tablets</p> <p style="font-size: 0.7em; margin: 0;">Form: Tablet Mims: Bladder-function disorders Class: Colour: Brown Shape: Oval Scoring: No</p>
<p style="font-size: 0.8em; margin: 5px 0;">Betmiga 50 mg Tablets</p>	<p style="font-size: 0.8em; margin: 5px 0;">Prograf 0.5 mg Capsules</p>	<p style="font-size: 0.8em; margin: 5px 0;">Prograf 1 mg Capsules</p>	<p style="font-size: 0.8em; margin: 5px 0;">Prograf 5 mg Capsules</p>	<p style="font-size: 0.8em; margin: 5px 0;">Vesicare 10 mg Tablets</p> <p style="font-size: 0.7em; margin: 0;">Form: Tablet</p>

Section 5: Interactions Checker

This feature allows the user to identify potentially harmful combinations of medications or medications unsuitable due to an allergy.

MIMS Drug Interactions is one of MIMS' Clinical Support Modules. The Drug Interactions information is compiled by a team of editors after an exhaustive review process, including ongoing searches of primary international literature, ADR bulletins, periodicals, and supporting literature associated with new products.

MIMS Interaction Checker
Identify potentially harmful combinations of medications or medications that may be unsuitable due to an allergy

MIMS IMGATEWAY

Prescribed Medicines
[Search]

Known Allergies
[Search]

Clear All [Check Interaction]

Drug Interactions Allergy Check


Interaction Results

Medicine	Route	Interacting medicine	Route	Severity	Documentation level
----------	-------	----------------------	-------	----------	---------------------

MIMS Drug Interactions are presented with the following information:


- **Medicine in search**
- **Route of administration**
- **Interacting medicine**
- **Severity level**
- **Documentation level**


There are two ways to start using the “Interactions Checker”:




1. Click the “Interaction Checker” in the navigation bar at the top left menu OR
2. Go to Shortcuts and select “MIMS Interaction Checker”.

To conduct a drug interaction check, follow these steps:






1. Type the name of the medicine by brand or generic molecule in the search box and select from the drop-down menu e.g., Warfarin.
2. Click the "Check Interaction" tab and the interaction search results will display all molecules that are known to cause an interaction with the medicine/s you entered.



3. To add more drugs for a more specific search, type another drug on the search box and select from the drop-down menu eg. Aspirin (Warfarin + Aspirin).
4. The interaction search results displayed are for all molecules that are known to cause an interaction with the medicine(s) you entered molecules of interest.
5. Click "Clear All" to clear all fields and begin with a new interaction search.


Section 6: Browse

The “Browse” function allows you to search for medicines by “Brand Name” or “Generic Name” in alphabetical order or by “Therapeutic Class”. Click on “Browse” in the top left menu to access this feature.




Browse by Brand


1. Click on the “Brands” tab.
2. Click on the first letter of the required name.
3. Click on the “Brand Name” of choice to display product information.
4. Click on the page number on the top right to view the list of products on that search page or click on arrows to go to any page other than the one you are viewing.



Browse by Therapeutic Class



1. Click on the “Therapeutic Classes” tab.
2. Click on a “Therapeutic Class” name, e.g., “Infections and Infestations”, to display all products in that class.
3. Click on the e.g.,” Penicillins” and the result will display all products that belong in that class.



By Indication



Medicines Information

Browse MIMS' wide variety of medicines information

Brands
Therapeutic Classes
Indications
Company

#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

< 1 2 3 4 5 ... 12 >

Abortion, therapeutic

Abrasion, corneal

Absence seizure

ACE inhibitor

Achondroplasia

Acne

Acquired immune deficiency syndrome

Acromegaly

ADHD (attention deficit hyperactivity disorder)

Adrenocortical insufficiency

Adrenoleukodystrophy

Affective disorder

Top

By Company



Medicines Information

Browse MIMS' wide variety of medicines information

Brands
Therapeutic Classes
Indications
Company

#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

< 1 2 3 >

A Menarini Australia Pty Ltd

AA-Med Pty Ltd

Abbott Australasia Pty Ltd

Abbott Products Pty Ltd

AbbVie Pty Ltd

Abraxis BioScience Australia Pty Ltd

Accelagen Pty Ltd

Accord Healthcare Pty Ltd

Actavis Australia Pty Ltd


Actelion Pharmaceuticals Australia Pty Limited

AdiraMedica Pty Ltd

Advanced Clinical Systems International

Top


Section 7: Tools and Resources



7.1 Tools


- **Don't Rush to Crush**

'Crush?' is SHPA's Don't Rush to Crush (DRTC) guide for the safe administration of medicines and is linked to available products.




- **Drug-Herb Interactions in the “IM Gateway”**

Check interactions between complementary and conventional medicines.



- **MIMS Interaction Checker**

Identify potentially harmful combinations of medications or medications that may be unsuitable due to an allergy.



- **Pill Identifier**

eMIMSplus offers a database of pill images that can be searched using the pill identifier tool. **(Refer to Section 4)**

- CYP450 Drug Interactions**

A guide to medicine interactions involving Cytochrome P450 enzymes.

MIMS CYP450 Drug Interactions
Medicine interactions involving Cytochrome P450 enzymes

Cytochrome P450 Isoenzyme Substrates, Inducers and Inhibitors

The table below has been designed for use in conjunction with MIMS abbreviated entries that describe the interactions of a drug in terms of effects on cytochrome P450 isoenzymes - either because the drug in question or the drug with which it may interact is a substrate for, induces or inhibits those enzymes.

The table is based on information in the product information, with additional reference sources listed below. It gives examples of drugs which may be implicated in clinically significant interactions but should not be regarded as a comprehensive list of all possible interactions. See the full product information for further information.

You can jump to a summary for each of the isoenzymes by clicking on the table headings.

Click [HERE](#) for a more detailed explanation of how to use this table.

Generic/Class	A B C D E F G H I K L M N O P Q R S T U V W Z									
	1A2	2A6	2B6	2C9	2C19	2C8	2D6	2E1	3A4	
Abemaciclib										sub
Abiraterone acetate						inhib	inhib			sub
Acalabrutinib										sub
Agomelatine	sub			inhib						
Alectinib										sub
Alfentanil										sub
Alfentanil hydrochloride										sub
Alfuzosin hydrochloride										sub
Alprazolam										sub
Ambrisentan					sub					sub
Amiodarone hydrochloride	inhib			inhib			inhib			inhib, sub

- Inhaler Technique Videos**

Videos developed by the Lung Foundation of Australia on how to use an inhaler properly to better manage respiratory symptoms.

Inhaler Technique Videos
Video series developed by Lung Foundation Australia [🔗](#)

Watch these short videos developed by Lung Foundation Australia to learn how to use your inhaler properly and better manage your respiratory symptoms. This will reassure you that you have the correct technique and you are receiving the full prescribed dose of the medicine.



Spacers
Lung Foundation Australia



Pressurised metered dose inhaler (pMDI)
Lung Foundation Australia



Eliпта
Lung Foundation Australia



Accuhaler
Lung Foundation Australia



Turbuhaler
Lung Foundation Australia



Rapihaler
Lung Foundation Australia




Breezhaler
Lung Foundation Australia




Handihaler
Lung Foundation Australia

- **Medicines in Pregnancy**

Compare the safety of medicines within therapeutic classes and identify potentially unsafe medicines during pregnancy.




1. To check the pregnancy category of a product, you can enter the Active ingredient, Product name, and/or Therapeutic class and will show the relevant results.
2. Click the hyperlink "(i)" and will show more information about the pregnancy category for the drug selected.




- **IV Compatibility**

Easy access to need-to-know information on medicine and solution compatibility for the safe administration of IV injectable medicines.



1. Enter the brand e.g., “Morphine Juno”.
2. It will show the incompatibility information of the selected product.
3. Clicking the “View Full PI” will show the Full Product Information of the selected product with the “IV Compatibility” icon opposite the brand name.



7.2 Resources

- **Drug in Sport – WADA Guide**

World Anti-Doping Code Prohibited List 2023 (Valid 1 January 2023 to 31 December 2023)

Drugs In Sport - WADA Guide

World Anti-Doping Code Prohibited List 2023 (Valid 1 January 2023 to 31 December 2023)

Adapted from the World Anti-Doping Agency (WADA) website (Prohibited List 2023, International Standard).
www.wada-ama.org

Substances And Methods Prohibited At All Times (In- And Out-Of-Competition)

Substances And Methods Prohibited At All Times (In- And Out-Of-Competition)

S0. Non-Approved Substances

S1. Anabolic Agents

S2. Peptide Hormones, Growth Factors, Related Substances, And Mimetics

S3. Beta-2 Agonists

M1. Manipulation Of Blood And Blood Components

M2. Chemical And Physical Manipulation

M3. Gene And Cell Doping

Substances And Methods Prohibited In-Competition

S6. Stimulants

S7. Narcotics

S8. Cannabinoids

S9. Glucocorticoids

Substances Prohibited In Particular Sports

P1. Beta-Blockers

The 2023 Monitoring Program*

International Standard For Therapeutic Use Exemptions (Istue)

PROHIBITED SUBSTANCES

S0. NON-APPROVED SUBSTANCES

All prohibited substances in this class are *Specified Substances*.

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

This class covers many different substances including but not limited to BPC-157.

S1. ANABOLIC AGENTS

All prohibited substances in this class are *non-Specified Substances*.

Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)

When administered exogenously, including but not limited to:

- 1-Androstenediol (5alpha-androst-1-ene-3beta,17beta-diol)
- 1-Androstenedione (5alpha-androst-1-ene-3,17-dione)

- **Medicines In Pregnancy Information – TGA**

Australian categorisation system and database for prescribing medicines in pregnancy.

Medicines In Pregnancy Information - TGA

Australian categorisation system and database for prescribing medicines in pregnancy

This information can also be obtained from the TGA website: www.tga.gov.au

Australian categorisation system for prescribing medicines in pregnancy

The Australian categorisation system and database for prescribing medicines in pregnancy have been developed by medical and scientific experts based on available evidence of risks associated with taking particular medicines while pregnant. This information is presented for the use of health professionals prescribing medicines to pregnant women, rather than for the general public to use. It is general in nature and is not presented as medical advice to health professionals or the public. It is not intended to be used as a substitute for a health professional's advice.

What does the Australian categorisation system take into account?

Most medicines cross the placenta. The categorisation system has taken into account the known harmful effects of medicines on the developing baby, including the potential to cause:

- birth defects
- unwanted pharmacological effects around the time of birth, which may or may not be reversible
- problems in later life

The categorisation system does not take into account the rare circumstance of an idiosyncratic reaction in the neonate to a medicine that crosses the placenta.

Situations for which the pregnancy category may not be valid

The pregnancy categorisation system only applies to recommended therapeutic doses in women. It cannot be assumed that the classifications assigned to individual medicines are valid in situations such as:

- Overdose
- Occupational exposure
- Other situations in which the recommended therapeutic dose has been exceeded

Australian Categorisation System For Prescribing Medicines In Pregnancy

What Does The Australian Categorisation System Take Into Account?

Situations For Which The Pregnancy Category May Not Be Valid

Why Do Some Products Have More Than One Pregnancy Category?

The Australian Categorisation System Is Not Hierarchical

Definitions Of The Australian Categories For Prescribing Medicines In Pregnancy

Category A

Category B1

Category B2

Category B3

Category C

Category D

Category X

Prescribing Medicines In Pregnancy Database

Source

Copyright

Disclaimer

• **PBS Brand Substitution**

A guide on Brand Substitution and Therapeutic Group Premiums

PBS Brand Substitution
Brand Substitution and Therapeutic Group Premiums

MIMS Therapeutic Classes

- + Alimentary System
- + Allergic Disorders
- + Analgesia
- + Cardiovascular System
- + Central Nervous System
- + Contraceptive Agents
- + Diagnostic Agents
- + Ear, Nose And Oropharynx
- + Endocrine And Metabolic Disorders
- + Eye
- + Genitourinary System
- + Herbal And Other Complementary Medicines
- + Immunology
- + Infections And Infestations
- + Musculoskeletal System
- + Neoplastic Disorders
- + Nutrition
- + Poisoning, Toxicity And Drug Dependence
- + Respiratory System
- + Skin
- + Surgical Preparations
- + Vitamins And Minerals

Brand Substitution and Therapeutic Group Premiums

Implementation of the Brand Substitution Legislation took effect from 1 December 1994. This applies to PBS determined therapeutically equivalent products prescribed as pharmaceutical benefits.

Prescribers, pharmacists and other healthcare professionals need to be familiar with, and understand the implications of, therapeutic equivalence, and they also need to know to which products therapeutic equivalence applies. To keep you up to date with which products are affected by this legislation (and also the Minimum Pricing Policy) we have stated which packs have therapeutic equivalence in the entries in MIMS Abbreviated Information.

Briefly, the **Brand Substitution Legislation** is summarised as follows.

From December 1994, brand substitution by pharmacists without reference to the prescriber was legal for PBS prescriptions where:

- the patient agrees to the substitution;
- the brands are identified in the Schedule of Pharmaceutical Benefits as being interchangeable;
- the doctor has not indicated on the prescription form that substitution is not to occur; and
- substitution is permitted under the relevant State or Territory legislation.

Associated with the Section name in MIMS entries for affected therapeutic groups is a list of interchangeable brands. Double click on the underlined text to display them (see also Sample Format).

For example: 100 mg 20's: **(G)** PBS/RPBS

The **(G)** indicates that brand substitution is permitted.

When prescribing an 'interchangeable' brand, the prescriber must decide whether or not brand substitution would be appropriate in the individual case. If the prescriber does not want brand substitution to occur, he or she must endorse the prescription **'Substitution not permitted'**. If brand substitution is acceptable to the patient and to the prescriber, the prescription can be written without this endorsement.

As mentioned previously, in addition to identifying products that are 'therapeutically equivalent', MIMS now indicates which products are affected by the Minimum Pricing Policy (i.e. attract a brand price premium).

In summary, the Government's **Minimum Pricing Policy** basically operates by:

• **Oral Contraceptives currently available in Australia**

Oral Contraceptives currently available in Australia

Product	No. of tablets	Estrogen content (mcg)				Progestogen content (mcg)							
		Ethinyl-estradiol	Mestranol	Estradiol	Estetrol	Levo-norgestrel	Nor-ethisterone	Desogestrel	Gestodene	Drospirenone	Dienogest	Nomegestrol	Etonogestrel
Combined oral contraceptives													
Femine-Tab ED 20/100 Lonest 20 ED	All	20	-	-	-	100	-	-	-	-	-	-	-
Loette Micrognon 20 ED Microlevin ED Micronelle 20 ED	All	20	-	-	-	100	-	-	-	-	-	-	-
Logynon ED	6	30	-	-	-	50	-	-	-	-	-	-	-
Trifeme	5	40	-	-	-	75	-	-	-	-	-	-	-
Triphasil	10	30	-	-	-	125	-	-	-	-	-	-	-
Triquilar ED	10	30	-	-	-	125	-	-	-	-	-	-	-
Eleanor 150/30 ED Evelyn 150/30 ED Femme-Tab ED 30/150 Lonest 30 ED Lorien ED Micrognon 30 ED Micronelle 30 ED Monselme Nordette	All	30	-	-	-	150	-	-	-	-	-	-	-
Madeline Marvelon 28	All	30	-	-	-	-	-	150	-	-	-	-	-
Brevinor 28 Nominin 28	All	35	-	-	-	-	500	-	-	-	-	-	-
Brevinor-1 28 Normin-1 28	All	35	-	-	-	-	1000	-	-	-	-	-	-
Micrognon 50 ED	All	50	-	-	-	125	-	-	-	-	-	-	-
Norinyl-1 28	All	-	50	-	-	-	1000	-	-	-	-	-	-
Minulet	All	30	-	-	-	-	-	75	-	-	-	-	-
Seasonique	84 7	30 10	-	-	-	150	-	-	-	-	-	-	-
Brooklyn Isabelle Fruiteille Yasmin Yelena	All	30	-	-	-	-	-	-	3000	-	-	-	-
Bella Brooke Yana Yaz	All	20	-	-	-	-	-	-	3000	-	-	-	-
Slinda	24	-	-	-	-	-	-	-	4000	-	-	-	-
Nextstellis	24	-	-	-	15 mcg	-	-	-	3 mg	-	-	-	-
Valette	All	30	-	-	-	-	-	-	-	2000	-	-	-

Section 8: Glossary of Terms

TERM	TERM	COMMENTS
FPI	Full Product Information	A document approved by the TGA, provided to MIMS by the pharmaceutical companies.
API	Abbreviated Product Information	Document compiled by MIMS from the Full PI, PBS, ADRAC, TGA, and included Gluten-free status, Sports categories, and indications if it is to be taken with food etc.
CMI	Consumer Medicines Information	The document is written specifically for Consumers and approved by the TGA.
TGA	Therapeutic Goods Administration	Australian Government group that approves medicines for registration and is responsible for FPI and CMI documents.
PBS	Pharmaceutical Benefit Scheme	Approved prescription pricing for medicines.
WADA	World Anti-Doping Agency	WADA is an international independent agency whose primary role is to develop, harmonize and coordinate anti-doping rules and policies across all sports and countries.